{"disease":{"id":"primary-immunodeficiency-disorders","name":"primary immunodeficiency disorders"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03394053","title":"The Mechanistic Biology of Primary Immunodeficiency Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02579967","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":354,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03188419","title":"Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide","phase":"","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03663933","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04339777","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04691622","title":"Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Children's National Research Institute","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}